Development and resolution of secondary autoimmunity after autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: Competition of plasma cells for survival niches?

摘要

Haematopoietic stem cell transplantation (HSCT) is an effective treatment for severe autoimmune diseases such as systemic lupus erythematosus (SLE). However, it is increasingly recognised that these patients have an added propensity to develop secondary autoimmune disorders.Here, we report on a 21-year-old male patient who received a CD34-selected autologous HSCT following conditioning with antithymocyte-globulin and cyclophosphamide (CYC) after written informed consent for refractory severe SLE with renal, haematological, mucocutaneous and musculoskeletal manifestations (SLEDAI 19).